GlassScriptPhysician profile
Dominique E Howard
NPI 1083673222
$29,288.01
in general payments reported to CMS, 2019-2025
31 companies · $2,350 in 2025
The $2,350 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $363 · 2021: $805 · 2022: $2,345 · 2023: $5,437 · 2024: $17K · 2025: $2,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $5,920 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,250 · Travel and Lodging: $90.91 · Education: $49.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,800.00 |
| Food and Beverage | $5,919.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,250.00 |
| Travel and Lodging | $90.91 |
| Education | $49.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $12,455.90 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $5,716.17 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $2,339.42 | 2022-2025 | Ibsrela |
| Abbvie INC. | $1,972.11 | 2019-2025 | |
| Janssen Biotech, INC. | $1,069.69 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Genzyme Corporation | $1,041.50 | 2022-2025 | |
| Celgene Corporation | $882.86 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $673.14 | 2022-2025 | General - Endochoice, Speedband Superview Super 7, Captivator II |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $569.92 | 2019-2025 | Xifaxan, Plenvu |
| Pfizer INC. | $544.81 | 2019-2025 | |
| Medtronic, INC. | $293.88 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $252.50 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.82 | 2019-2025 | Eohilia |
| Fujifilm Healthcare Americas Corporation | $195.66 | 2022 | |
| Conmed Corporation | $150.68 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $143.83 | 2025 | |
| Corcept Therapeutics | $128.55 | 2024 | Korlym |
| Novo Nordisk INC | $95.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $84.00 | 2023-2024 | Linzess |
| Lilly USA, LLC | $61.03 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $56.91 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $49.56 | 2025 | |
| Qol Medical, LLC | $47.30 | 2019-2024 | Sucraid |
| Stryker Corporation | $42.41 | 2024 | Neptune |
| Celltrion USA INC. | $41.80 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $34.56 | 2019 | |
| Amgen INC. | $32.25 | 2022 | |
| Evoke Pharma, INC. | $31.29 | 2023-2025 | Gimoti |
| Olympus America INC. | $24.79 | 2025 | Evis Exera III Colonovideoscope |
| Aimmune Therapeutics, INC. | $23.92 | 2025 | Zenpep |
| Vivus LLC | $20.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominique Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.